[Experimental intranasal infection of cattle with Aujeszky's disease virus (author's transl)].

G. Wittmann,U. Höhn,F. Weiland,H. Böhm

1981-09-05

Abstract:

What problem does this paper attempt to address?

Targets of drug action.

A. Burgen

DOI: https://doi.org/10.1146/ANNUREV.PHARMTOX.40.1.1

Abstract:This article considers early work from the author's laboratory on muscarinic receptor specificity, subtypes, and conformational variability, with the use of nuclear magnetic resonance in pharmacology and the conformational variants of dihydrofolate reductase and general questions of receptors. It also considers some current approaches to drug development and receptor function, particularly as influenced by increasing knowledge of three-dimensional structure of receptors.
Pharmacokinetics and Molecular Docking studies of Plant-Derived Natural Compounds to Exploring Potential Anti-Alzheimer Activity

Aftab Alam,Naaila Tamkeen,Nikhat Imam,Anam Farooqui,Mohd Murshad Ahmed,Shahnawaz Ali,Md Zubbair Malik,Romana Ishrat

DOI: https://doi.org/10.48550/arXiv.1709.10374

2017-07-19

Abstract:Alzheimer disease (AD) is the leading cause of dementia, accounts for 60 to 80 percent cases. Two main factors called beta amyloid plaques and tangles are prime suspects in damaging and killing nerve cells. However, oxidative stress, the process which produces free radicals in cells, is believed to promote its progression to the extent that it may responsible for the cognitive and functional decline observed in AD. As of today there are few FDA approved drugs in the market for treatment, but their cholinergic adverse effect, potentially distressing toxicity and limited targets in AD pathology limits their use. Therefore, it is crucial to find an effective compounds to combat AD. We choose 45 plant derived natural compounds that have antioxidant properties to slow down disease progression by quenching free redicals or promoting endogenous antioxidant capacity. However, we performed molecular docking studies to investigate the binding interactions between natural compounds and 13 various anti Alzheimer drug targets. Three known Cholinesterase inhibitors (Donepezil, Galantamine and Rivastigmine) were taken as reference drugs over natural compounds for comparison and drug likeness studies. Few of these compounds showed good inhibitory activity besides anti oxidant activity. Most of these compounds followed pharmacokinetics properties that make them potentially promising drug candidates for the treatment of Alzheimer disease.

Quantitative Methods
Molecular docking analysis of marine phytochemicals with BACE-1

Deepak Sheokand,Annu Grewal,Pawan Kumar,Raveena Chauhan,Vandana Saini,Ajit Kumar

DOI: https://doi.org/10.6026/973206300200151

2024-02-29

Bioinformation

Abstract:Alzheimer's disease (AD), a debilitating neurodegenerative condition, is characterized by progressive cognitive decline brought about by the deposition of amyloid beta (Aβ) plaques in the brain initiates downstream neuronal dysfunction and death in AD pathogenesis. The β-secretase (BACE-1) enzyme plays a crucial role in generating Aβ from amyloid precursor protein (APP). Hence, we report the virtual screening of marine phytochemicals as BACE-1 inhibitors. 2583 compounds, retrieved from Comprehensive Marine Natural Product Database (CMNPD), were primarily screened for drug-likeliness and blood-brain barrier permeability using admetSAR 2.0 and in-house BBBper tool and resulted in a total of 635 phytochemicals, selected for further docking studies using BACE-1 as target receptor and Atabecestat as standard BACE-1 inhibitor. Seven of 635 compounds docked against BACE-1, showed better binding affinities than Atabecestat, with the red algal metabolite lactodehydrothyrsiferol showing lowest binding energy of -10.83 kcal/mol. These compounds are worth investigating further to assess their neuroprotective efficacy and pharmacokinetic properties. The study also provides a rational framework to uncover novel pharmacophores from marine sources for AD therapy acting through BACE-1 inhibition.
Identification of acetylcholinesterase inhibitors from traditional medicinal plants for Alzheimer's disease using in silico and machine learning approaches

Md. Tarikul Islam,Md. Aktaruzzaman,Ahmed Saif,Al Riyad Hasan,Md. Mehedi Hasan Sourov,Bratati Sikdar,Saira Rehman,Afrida Tabassum,Syed Abeed-Ul-Haque,Mehedi Hasan Sakib,Md. Muntasir Alam Muhib,Md. Ali Ahasan Setu,Faria Tasnim,Rifat Rayhan,Mohamed M. Abdel-Daim,Md. Obayed Raihan

DOI: https://doi.org/10.1039/d4ra05073h

IF: 4.036

2024-11-02

RSC Advances

Abstract:Acetylcholinesterase (AChE) holds significance in Alzheimer's disease (AD), where cognitive impairment correlates with insufficient acetylcholine levels. AChE's role involves the breakdown of acetylcholine, moderating cholinergic neuron activity to prevent overstimulation and signal termination. Hence, inhibiting AChE emerges as a potential treatment avenue for AD. A library of 2500 compounds, derived from 25 traditionally used medicinal plants, was constructed using the IMPAAT database of traditional medicinal plants. The canonical SMILES of these compounds were collected and underwent virtual screening based on physicochemical properties, with subsequent determination of IC 50 values for the screened compounds followed by analysis using machine learning (ML). Subsequently, a molecular docking study elucidated both binding affinity and interactions between these compounds and AChE. The top three compounds, exhibiting robust binding affinities, underwent MM-GBSA analysis for molecular docking validation, succeeded by pharmacokinetics and toxicity evaluations to gauge safety and efficacy. These three compounds underwent MD simulation studies to assess protein–ligand complex conformational stability. Additionally, Density Functional Theory (DFT) was employed to ascertain HOMO, LUMO, energy gap, and molecular electrostatic potential. Among 2500 compounds, physicochemical properties-based virtual screening identified 80 with good properties, of which 32 showed promising IC 50 values. Molecular docking studies of these 32 compounds revealed various binding energies with AChE, with the best three compounds (CID 102267534, CID 15161648, CID 12441) selected for further analysis. MM-GBSA studies confirmed the promising binding energies of these three compounds, validating the molecular docking study. Further, the MD simulation studies have confirmed the structural and conformational stability of these three protein–ligand complexes. Finally, DFT calculations revealed favorable chemical features of these compounds. Thus, we can conclude that these three compounds (CID 102267534, CID 15161648, CID 12441) may inhibit the activity of AChE and can be useful as a treatment for Alzheimer's disease.

chemistry, multidisciplinary
Docking Studies on Ache and Tau Proteins with Marine Bioactive Compound Squalene, A New Approach to Design Anti-Alzheimer’s Drug Targets

Praveen Kukkarasapalli,Yellamma Kuna

DOI: https://doi.org/10.47583/ijpsrr.2021.v70i02.031

2021-10-15

International Journal of Pharmaceutical Sciences Review and Research

Abstract:Natural bioactive compounds of Marine origin have attracted the attention of many biologists and chemists in the world over for the last five decades because it has proven to be a rich source of structurally diverse and complex compounds exhibiting numerous interesting biological functions. At present, many research findings have provided insight into biological activities of marine natural compounds such as antioxidant- and anti-cholinesterase activity and neuroprotective effects on neurodegenerative diseases, viz. Alzheimer’s and Parkinson’s. The main pathological hallmarks of AD is the formation senile plaques, neurofibrillary tangles and the most incredible physiological and biochemical changes are reduction in acetylcholine (ACh) levels in the hippocampus and cortex of the brain and loss of memory, decaying language etc. Present study is focused on to enhance the acetylcholine levels and subsequently to prevent the formation of Senile Plaques and Neuro Fibrillary Tangles in tau protein responsible for Alzheimer’s disease by using natural bioactive compound Squalene. Computational Biology and Bio-informatics have the potential not only to speed up the drug discovery process but reduces the costs. Further, they also change the way drugs are designed by using Docking Techniques employed to dock a set of marine bioactive compounds within the active site region of 1B41 & 2V17 by using Auto Dock vina. The docking simulation clearly predicted the interaction and highest binding energy docking scores against Squalene, analogues were retrieved from ZINC database i.e. ZINC 0118 (-8.9) and ZINC 0142 (-8.3) for 4B05 & 2V17 enzymes respectively. Further, we Studied visualization aspects in PyMol and also satisfied the biological activity predictions like OSIRIS, Molinspiration and PASS Prediction results by inhibiting the activity of Tau and Acetyl Cholinesterase receptors in AD.
Network pharmacology‒based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer's disease

Rui Xie,Feng Chen,Yixuan Ma,Wen Hu,Qiang Zheng,Jinguo Cao,Yi Wu

DOI: https://doi.org/10.3389/fphar.2023.1249632

IF: 5.6

2023-10-19

Frontiers in Pharmacology

Abstract:In recent years, the Alzheimer's disease (AD) epidemic has become one of the largest global healthcare crises. Besides, the available systemic therapies for AD are still inadequate. Due to the insufficient therapeutic options, new treatment strategies are urgently needed to achieve a satisfactory therapeutic effect. Marine bio-resources have been accepted as one of the most economically viable and sustainable sources with potential applications for drug discovery and development. In this study, a marine cyanobacteria– Synechococcus sp. XM-24 was selected as the object of research, to systematically investigate its therapeutic potential mechanisms for AD. The major active compounds derived from the Synechococcus sp. biomass were identified via pyrolysis-gas chromatography-mass spectrometry (GC-MS), and 22 compounds were identified in this strain. The most abundant chemical compounds was (E)-octadec-11-enoic acid, with the peak area of 30.6%. Follow by tridecanoic acid, 12-methyl- and hexadecanoic acid, with a peak area of 23.26% and 18.23%, respectively. GC-MS analysis also identified indolizine, isoquinoline, 3,4-dihydro- and Phthalazine, 1-methyl-, as well as alkene and alkane from the strain. After the chemical toxicity test, 10 compounds were finally collected to do the further analysis. Then, network pharmacology and molecular docking were adopted to systematically study the potential anti-AD mechanism of these compounds. Based on the analysis, the 10 Synechococcus- derived active compounds could interact with 128 related anti-AD targets. Among them, epidermal growth factor receptor (EGFR), vascular endothelial growth factor A (VEGFA) and mitogen-activated protein kinase 3 (MAPK3) were the major targets. Furthermore, the compounds N-capric acid isopropyl ester, (E)-octadec-11-enoic acid, and 2H-Pyran-2,4(3H)-dione, dihydro-6-methyl- obtained higher degrees in the compounds-intersection targets network analysis, indicating these compounds may play more important role in the process of anti-AD. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that these active compounds exert the anti-AD effects mainly through PI3K-Akt signaling pathway, neuroactive ligand-receptor interaction and ras signaling pathway. Our study identified Synechococcus- derived bioactive compounds have the potential for application to AD by targeting multiple targets and related pathways, which will provide a foundation for future research on applications of marine cyanobacteria in the functional drug industry.

pharmacology & pharmacy
In silico identification of colchicine derivatives as novel and potential inhibitors based on molecular docking and dynamic simulations targeting multifactorial drug targets involved in Alzheimer's disease

Adity Raturi,Vikas Yadav,Nasimul Hoda,Naidu Subbarao,Saif Ali Chaudhry

DOI: https://doi.org/10.1080/07391102.2023.2263586

Abstract:Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, characterized by a gradual and steady deterioration in cognitive function over time. At least 50 million people worldwide are considered to have AD or another form of dementia. AD is marked by a gradual decline in cognitive abilities, memory deterioration and neurodegenerative transformations within the brain. The intricate and multifaceted nature of polygenic AD presents significant challenges within the landscape of drug development. The pathophysiology of AD unfolds in a non-linear and dynamic pattern, encompassing various systems and giving rise to a multitude of factors and hypotheses that contribute to the disease's onset. These encompass theories such as the beta-amyloid hypothesis, cholinergic hypothesis, tau hypothesis, oxidative stress and more. In the realm of drug development, polypharmacological drug profiles have emerged as a strategy that can yield combined or synergistic effects, effectively mitigating undesirable side effects and significantly enhancing the therapeutic efficacy of essential medications. With this concept in mind, our in-silico study sought to delve into the binding interactions of a diverse array of colchicine derivative compounds. These derivatives are chosen for their potential anti-inflammatory, antioxidant, anti-neurodegenerative and neuroprotective properties against Alzheimer's and other neurodegenerative diseases. We investigated compound interactions with AD-related targets, utilizing comprehensive molecular docking and dynamic simulations. COM111X showed impressive docking with acetylcholinesterase, indicating potential as an anti-Alzheimer's drug. COM112Y displayed strong docking scores with PDE4D and butyrylcholinesterase, suggesting dual inhibition for Alzheimer's treatment. Further in vitro and in vivo studies are warranted to explore these findings.Communicated by Ramaswamy H. Sarma.
Biological Potential, Gastrointestinal Digestion, Absorption, and Bioavailability of Algae-Derived Compounds with Neuroprotective Activity: A Comprehensive Review

Bruna Martins,Mónica Vieira,Cristina Delerue-Matos,Clara Grosso,Cristina Soares

DOI: https://doi.org/10.3390/md20060362

2022-05-28

Marine Drugs

Abstract:Currently, there is no known cure for neurodegenerative disease. However, the available therapies aim to manage some of the symptoms of the disease. Human neurodegenerative diseases are a heterogeneous group of illnesses characterized by progressive loss of neuronal cells and nervous system dysfunction related to several mechanisms such as protein aggregation, neuroinflammation, oxidative stress, and neurotransmission dysfunction. Neuroprotective compounds are essential in the prevention and management of neurodegenerative diseases. This review will focus on the neurodegeneration mechanisms and the compounds (proteins, polyunsaturated fatty acids (PUFAs), polysaccharides, carotenoids, phycobiliproteins, phenolic compounds, among others) present in seaweeds that have shown in vivo and in vitro neuroprotective activity. Additionally, it will cover the recent findings on the neuroprotective effects of bioactive compounds from macroalgae, with a focus on their biological potential and possible mechanism of action, including microbiota modulation. Furthermore, gastrointestinal digestion, absorption, and bioavailability will be discussed. Moreover, the clinical trials using seaweed-based drugs or extracts to treat neurodegenerative disorders will be presented, showing the real potential and limitations that a specific metabolite or extract may have as a new therapeutic agent considering the recent approval of a seaweed-based drug to treat Alzheimer's disease.

pharmacology & pharmacy,chemistry, medicinal
Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review

Jia Yee Lee,Chiew Yen Wong,Rhun Yian Koh,Chooi Ling Lim,Yih Yih Kok,Soi Moi Chye

DOI: https://doi.org/10.59249/JNKB9714

2024-06-28

Abstract:Neuroinflammation, toxic protein aggregation, oxidative stress, and mitochondrial dysfunction are key pathways in neurodegenerative diseases like Alzheimer's disease (AD). Targeting these mechanisms with antioxidants, anti-inflammatory compounds, and inhibitors of Aβ formation and aggregation is crucial for treatment. Marine algae are rich sources of bioactive compounds, including carbohydrates, phenolics, fatty acids, phycobiliproteins, carotenoids, fatty acids, and vitamins. In recent years, they have attracted interest from the pharmaceutical and nutraceutical industries due to their exceptional biological activities, which include anti-inflammation, antioxidant, anticancer, and anti-apoptosis properties. Multiple lines of evidence have unveiled the potential neuroprotective effects of these multifunctional algal compounds for application in treating and managing AD. This article will provide insight into the molecular mechanisms underlying the neuroprotective effects of bioactive compounds derived from algae based on in vitro and in vivo models of neuroinflammation and AD. We will also discuss their potential as disease-modifying and symptomatic treatment strategies for AD.
Structural and molecular features of acetylcholinesterase targeting small molecules: Leveraging in-silico tools to combat Alzheimer's disease

A. Haque,Khalaf M. Alenezi,Mohd. Saeed Maulana Abdul Rasheed

DOI: https://doi.org/10.1039/d4nj02065k

IF: 3.3

2024-09-03

New Journal of Chemistry

Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative condition that leads to the gradual decline of neuronal cells. Despite significant interest and investment, complete prevention or treatment for AD and related dementia is still limited. The human acetylcholinesterase (hAChE) enzyme is a promising target for combating AD as it plays a crucial role in metabolising the neurotransmitter acetylcholine, which is essential for cognitive function and memory. The present study employed a multi-step approach, beginning with molecular docking to virtually screen 73,531 compounds from the PubChem library. Subsequently, we used Glide extra precision molecular docking and molecular dynamics (MD) simulations at 500 ns to narrow down a list of three candidate compounds (PubChem CID: 73058259, 141100002, and 44285707). The pharmacological and ADMET properties of the top compounds were determined using multiple tools. The MD study at 500 ns revealed that all the selected ligands formed stable complexes with AChE. The trajectories of the ligands were stable, similar/better to the reference compound (donepezil), and identified compounds have high drug-like features. This study presents the unique findings of structural and molecular features of new hAChE inhibitors and their dynamics, which have not been studied before. These insights could pave the way for developing more effective treatments for various neurological conditions.

chemistry, multidisciplinary
A computational approach to identify phytochemicals as potential inhibitor of acetylcholinesterase: Molecular docking, ADME profiling and molecular dynamics simulations

Mahir Azmal,Md. Sahadot Hossen,Md. Naimul Haque Shohan,Rashid Taqui,Abbeha Malik,Ajit Ghosh

DOI: https://doi.org/10.1371/journal.pone.0304490

IF: 3.7

2024-06-05

PLoS ONE

Abstract:Inhibition of acetylcholinesterase (AChE) is a crucial target in the treatment of Alzheimer's disease (AD). Common anti-acetylcholinesterase drugs such as Galantamine, Rivastigmine, Donepezil, and Tacrine have significant inhibition potential. Due to side effects and safety concerns, we aimed to investigate a wide range of phytochemicals and structural analogues of these compounds. Compounds similar to the established drugs, and phytochemicals were investigated as potential inhibitors for AChE in treating AD. A total of 2,270 compound libraries were generated for further analysis. Initial virtual screening was performed using Pyrx software, resulting in 638 molecules showing higher binding affinities compared to positive controls Tacrine (-9.0 kcal/mol), Donepezil (-7.3 kcal/mol), Galantamine (-8.3 kcal/mol), and Rivastigmine (-6.4 kcal/mol). Subsequently, ADME properties were assessed, including blood-brain barrier permeability and Lipinski's rule of five violations, leading to 88 compounds passing the ADME analysis. Among the rivastigmine analogous, [3-(1-methylpiperidin-2-yl)phenyl] N,N-diethylcarbamate showed interaction with Tyr123, Tyr336, Tyr340, Phe337, Trp285 residues of AChE. Tacrine similar compounds, such as 4-amino-2-styrylquinoline, exhibited bindings with Tyr123, Phe337, Tyr336, Trp285, Trp85, Gly119, and Gly120 residues. A phytocompound (bisdemethoxycurcumin) showed interaction with Trp285, Tyr340, Trp85, Tyr71, and His446 residues of AChE with favourable binding. These findings underscore the potential of these compounds as novel inhibitors of AChE, offering insights into alternative therapeutic avenues for AD. A 100ns simulation analysis confirmed the stability of protein-ligand complex based on the RMSD, RMSF, ligand properties, PCA, DCCM and MMGBS parameters. The investigation suggested 3 ligands as a potent inhibitor of AChE which are [3-(1-methylpiperidin-2-yl)phenyl] N,N-diethylcarbamate, 4-Amino-2-styrylquinoline and bisdemethoxycurcumin. Furthermore, investigation, including in-vitro and in-vivo studies, is needed to validate the efficacy, safety profiles, and therapeutic potential of these compounds for AD treatment.

multidisciplinary sciences
Early Re‐operation After Surgery for Calculous Biliary Tract Disease

N. Lygidakis

DOI: https://doi.org/10.1111/j.1742-1241.1982.tb08368.x

1982-04-01

Abstract:Aetiology of Calculous Biliary Tract Disease in 3.926 Operations (1969·1980) MATERIALS AND METHODS From January 1964 to June 1980. 3.926 operations on the biliary tract for lithiasis were carried out in Athens. The aetiology is shown in Table I. Six hundred and forty-six patients sooner or later after their initial operation on the biliary tree will require further surgery (Glenn. 1972; Buhrene, 1976; Schwartz. 1974). On the other hand the number of immediate re-operations on the biliary tract is reported to range between 2 and 40/<, (White. 1973). Apart from further discomfort to the patient and embarrassment to the surgeon. re-exploration of the bile ducts is associated with a morbidity which is twice as high compared to that of the first choledochotomy and four times that of the uncomplicated cholecystectomy (Sterling. 1964). It is clear that with improvement in the surgical technique and anaesthesia the number of immediate re-operations is greatly reduced. but nevertheless it can and has to be further diminished. In the present study we present our experience with early re-operation on the biliary tree after surgery for biliary calculous disease in 35 patients. There is also an analysis of different diagnostic and therapeutic problems which have been encountered in dealing with this group of patients. In this study reoperations for' residual or retained' common bile duct stones are not included.
Utilizing marine algal metabolites to fight neurodegenerative diseases

Bindu Naik,Shruti Richa,Shivangi Bharadwaj,Sadhna Mishra,Vijay Kumar,Vivek Kumar,Per Erik Joakim Saris,Arun Kumar Gupta,Ritesh Mishra,Uttam Gupta,Sarvesh Rustagi,Manpreet Singh Preet

DOI: https://doi.org/10.3389/fmars.2024.1370839

IF: 5.247

2024-05-25

Frontiers in Marine Science

Abstract:Marine algae are thought to be a source of various metabolites that have a wide range of positive effects on human health. The pharmacological properties of algal metabolites, including their antioxidant, anti-inflammatory, cholesterol homeostasis, protein clearance, and anti-amyloidergic effects, lend credence to their protective efficacy against oxidative stress, neuroinflammation, mitochondrial dysfunction, and impaired proteostasis, all of which are involved in the pathophysiology of neurodegenerative disorders. There are currently no clinical trials on the effects of marine algae on neuroinflammation; however, considering the significant biological activities that have been established by in vitro and animal research, we expect that there will be clinical trials on this topic in the not-too-distant future. The most recent and important findings on the potentially neuroprotective effects of the anti-inflammatory properties of marine algae were chosen for this study. Next, we conducted a literature review on the neuroprotective potential of algal compounds, along with the underlying pharmacological mechanism, and finally, we evaluated recent advances in therapeutics.

marine & freshwater biology
Nurse practitioner and physician's assistant clinics in rural California. Part I: issues.

W. Morgan,N. D. Sullivan

1980-02-01

Western Journal of Medicine

Abstract:The primary health care needs of at least 26 rural California communities are being served by nurse practitioners (NP's) or physician's assistants (PA's). All of these have physician supervision and support. NP's and PA's have proved to be acceptable and effective. With 230 rural areas in California identified as having unmet health care needs, this type of service is likely to increase and should be supported.NP/PA clinics serve total populations or concentrate on Indians, Chicanos or the poor. Many barriers have been overcome, especially over the past four years, to allow these clinics to flourish and increase in number. The availability of nurse practitioners and physician's assistants has increased due to support to schools and to school policies. Clinic funding has greatly improved; federal funds for general rural clinics, Indians, migrants, family planning and maternalchild health have been greatly supplemented by California state funds. Beginning in 1978, rural NP and PA services can be reimbursed by Medicare and Medi-Cal (California's Medicaid program).Since 1975 state laws have defined PA and NP roles broadly, and these roles are more precisely defined at the local level. Although nurse practitioners and physician's assistants generally cannot prescribe or dispense drugs (a major problem in many clinics), demonstration legislation allows special pilot projects to do both. As remaining funding and legal problems are corrected, NP's and PA's will serve an even greater role in rural areas.
Potential benefits of marine-derived compounds for slowing the advancement of Alzheimer's disease

Aditya Malan,Manjusha Choudhary,Prabhjeet Kaur Bamrah,Dipender Kumari

DOI: https://doi.org/10.1080/10286020.2024.2409869

2024-10-09

Journal of Asian Natural Products Research

Abstract:The incidence of Alzheimer's is increasing and poses a significant social and economic burden. The pathogenesis involved in the expansion of AD includes neuronal oxidative damage, tau phosphorylation, amyloid beta aggregation, neuroinflammation, etc. Despite enormous efforts, there is currently no effective treatment or cure for this condition in the allopathic system. Marine compounds are appealing options and have a strong neuroprotective impact. Marine-derived compounds from sponges, algae, and marine invertebrates can be used for neuroprotection, with fewer adverse effects than synthetic drugs. Various compounds such as bryostatin-1, docosahexaenoic acid, spirolides, and astaxanthin, GV-971, have demonstrated outstanding activity and bioavailability.

pharmacology & pharmacy,chemistry, medicinal, applied,plant sciences
Complementary marital roles of male heroin addicts: evolution and intervention tactics.

T. Kosten,B. Jalali,H. Kleber

DOI: https://doi.org/10.3109/00952998209002619

The American Journal of Drug and Alcohol Abuse

Abstract:Using Haley's concept of complementary and symmetrical relationships, we intensively studied the role relationships of 28 male heroin addicts and their spouses. These couples had no symmetrical role relationships, but had an alternating sequence of two complementary role relationships. These complementary roles sequentially alternated from a compliant child with a nurturing mother, when the wife would deny her husband's drug abuse; to a rebellious son with a policing mother, when a financial or legal crisis would force her to confront his addiction. After this crisis, the couple entered treatment in the unstable complementary roles of contrite child and policing mother. During treatment, the wife was educated and supported to confront early signs of drug abuse, thus avoiding its denial, and the couple was encouraged to develop symmetrical roles by beginning to share minor responsibilities.
New Drugs from Marine Organisms in Alzheimer’s Disease

Patrizia Russo,Aliaksei Kisialiou,Palma Lamonaca,Rossana Moroni,Giulia Prinzi,Massimo Fini

DOI: https://doi.org/10.3390/md14010005

2015-12-25

Marine Drugs

Abstract:Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans.

pharmacology & pharmacy,chemistry, medicinal
In Silico Discovery and Predictive Modeling of Novel Acetylcholinesterase (AChE) Inhibitors for Alzheimer's Treatment

Humaera Noor Suha,Md Shamim Hossain,Shofiur Rahman,Abdullah Alodhayb,Md Mainul Hossain,Sarkar M A Kawsar,Raymond Poirier,Kabir M Uddin

DOI: https://doi.org/10.2174/0115734064304100240511112619

2024-05-27

Abstract:Introduction: Alzheimer's disease, akin to coronary artery disease of the heart, is a progressive brain disorder driven by nerve cell damage. Method: This study utilized computational methods to explore 14 anti-acetylcholinesterase (AChE) derivatives (1 ̶ 14) as potential treatments. By scrutinizing their interactions with 11 essential target proteins (AChE, Aβ, BChE, GSK-3β, MAO B, PDE-9, Prion, PSEN-1, sEH, Tau, and TDP-43) and comparing them with established drugs such as donepezil, galantamine, memantine, and rivastigmine, ligand 14 emerged as notable. During molecular dynamics simulations, the protein boasting the strongest bond with the critical 1QTI protein and exceeding drug-likeness criteria also exhibited remarkable stability within the enzyme's pocket across diverse temperatures (300 ̶ 320 K). In addition, we utilized density functional theory (DFT) to compute dipole moments and molecular orbital properties, including assessing the thermodynamic stability of AChE derivatives. Result: This finding suggests a welldefined, potentially therapeutic interaction further supported by theoretical and future in vitro and in vivo investigations. Conclusion: Ligand 14 thus emerges as a promising candidate in the fight against Alzheimer's disease.
Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future

Di Hu,Yating Jin,Xiangqi Hou,Yinlong Zhu,Danting Chen,Jingjing Tai,Qianqian Chen,Cui Shi,Jing Ye,Mengxu Wu,Hong Zhang,Yanbin Lu

DOI: https://doi.org/10.3390/md21010043

2023-01-05

Abstract:Alzheimer's disease (AD), a neurodegenerative disease, is one of the most intractable illnesses which affects the elderly. Clinically manifested as various impairments in memory, language, cognition, visuospatial skills, executive function, etc., the symptoms gradually aggravated over time. The drugs currently used clinically can slow down the deterioration of AD and relieve symptoms but cannot completely cure them. The drugs are mainly acetylcholinesterase inhibitors (AChEI) and non-competitive N-methyl-D-aspartate receptor (NDMAR) antagonists. The pathogenesis of AD is inconclusive, but it is often associated with the expression of beta-amyloid. Abnormal deposition of amyloid and hyperphosphorylation of tau protein in the brain have been key targets for past, current, and future drug development for the disease. At present, researchers are paying more and more attention to excavate natural compounds which can be effective against Alzheimer's disease and other neurodegenerative pathologies. Marine natural products have been demonstrated to be the most prospective candidates of these compounds, and some have presented significant neuroprotection functions. Consequently, we intend to describe the potential effect of bioactive compounds derived from marine organisms, including polysaccharides, carotenoids, polyphenols, sterols and alkaloids as drug candidates, to further discover novel and efficacious drug compounds which are effective against AD.
Testing of Refrigeration Compressors without Condensation

R. Dirlea,J. Hannay,J. Lebrun

Abstract:This study presents the design procedure and the experimental results obtained on a new test bench for refrigeration compressors. The main components of the plant are: the compressor to be tested, a water cooled heat exchanger, an expansion valve and a refrigerant vesseL The test bench can be used for: performance evaluation of the compressor (refrigerant flow rate can be found on a heat balance on the gas cooler and after it can be converted to cooling capacity), long live tests and quality control for compressors. The advantages of a« fully gas cycle» are: low energy consumption refrigerant charge of the plant, small inertia of the plant. AU global heat transfer coefficient cspecific heat h specific enthalpy Mmass M mass flow rate ppressure Q heat flow rate Ssurface t temperature U internal energy vspecific volume Vvolume Vvolumetric flow rate W -power consumption NOMENCLATURE Greek: .1.,8 difference .1.8m mean log temperature difference s efficiency y isentropic coefficient -r -time pdensity INTRODUCTION Index: amb ambient cp compressor cr critical exexhaust HE heat exchanger HP high pressure side is isentropic LP low pressure side R refrigerant susupply swswept vol volumetric wwater Performance evaluation of refrigeration compressors include estimation of cooling capacity for given setpoints. International Standard ISO 917 [I] describes 9 test methods for the determination of the cooling capacity: A. secondary fluid calorimeter in suction line B. flooded system refrigerant calorimeter in suction line C. dry system refrigerant calorimeter D refrigerant vapour flow meter in the suction line or in the discharge line E. refrigerant liquid flowmeter F. water cooled condenser G. partial condensation of refrigerant H. calorimeter in the discharge line For methods A, Band C, the cooling capacity is found by direct measurement (heat supplied to the evaporator). Methods D and E allow a direct measurement of refrigerant flow rate. Methods F, G and H estimate the refrigerant flow rate using an energy balance. Consequently, for methods D to H, the cooling capacity is found using the thermodynamic properties of the fluid. The criteria of an efficient test bench for compressors should be: • good precision • facility of control • low energy consumption • small inertia (test point and steady sate conditions should be reached as quickly as possible)

[Experimental intranasal infection of cattle with Aujeszky's disease virus (author's transl)].

Targets of drug action.

Pharmacokinetics and Molecular Docking studies of Plant-Derived Natural Compounds to Exploring Potential Anti-Alzheimer Activity

Molecular docking analysis of marine phytochemicals with BACE-1

Identification of acetylcholinesterase inhibitors from traditional medicinal plants for Alzheimer's disease using in silico and machine learning approaches

Docking Studies on Ache and Tau Proteins with Marine Bioactive Compound Squalene, A New Approach to Design Anti-Alzheimer’s Drug Targets

Network pharmacology‒based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer's disease

In silico identification of colchicine derivatives as novel and potential inhibitors based on molecular docking and dynamic simulations targeting multifactorial drug targets involved in Alzheimer's disease

Biological Potential, Gastrointestinal Digestion, Absorption, and Bioavailability of Algae-Derived Compounds with Neuroprotective Activity: A Comprehensive Review

Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review

Structural and molecular features of acetylcholinesterase targeting small molecules: Leveraging in-silico tools to combat Alzheimer's disease

A computational approach to identify phytochemicals as potential inhibitor of acetylcholinesterase: Molecular docking, ADME profiling and molecular dynamics simulations

Early Re‐operation After Surgery for Calculous Biliary Tract Disease

Utilizing marine algal metabolites to fight neurodegenerative diseases

Nurse practitioner and physician's assistant clinics in rural California. Part I: issues.

Potential benefits of marine-derived compounds for slowing the advancement of Alzheimer's disease

Complementary marital roles of male heroin addicts: evolution and intervention tactics.

New Drugs from Marine Organisms in Alzheimer’s Disease

In Silico Discovery and Predictive Modeling of Novel Acetylcholinesterase (AChE) Inhibitors for Alzheimer's Treatment

Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future

Testing of Refrigeration Compressors without Condensation